ABSTRACT
Erlotinibis known as a key drug for the treatment of non-small-cell lung cancer. It is known to interact with gastric acid suppressing medications(AS). Concurrent administration of erlotinibwith AS is reported to decrease AUC and Cmax of erlotinib. From the result of a survey on concurrent administration of erlotinib with AS in our hospital, we considered that intake of erlotinib between meals in the morning and intake of AS after dinner or at bedtime certainly reduce the chance of drug interactions to a minimum. We suggested a direction of use of erlotinibto the doctors who used to prescribe this medication in their daily medical practice. We surveyed the doctors' perceptions of drug interactions. The results of the survey showed that 29% of the doctors were not concerned about drug interactions, although 81% of the doctors approved our proposal. By providing a suggestion for drug administration by analyzing drug information, the expectations of the doctors can be met and it also demonstrates the efficiency of pharmacists.
Subject(s)
Carcinoma, Non-Small-Cell Lung , Erlotinib Hydrochloride/adverse effects , Lung Neoplasms , Drug Interactions , Gastric Acid , Humans , Surveys and QuestionnairesABSTRACT
Anticancer drug-associated dermatopathy tends to be disregarded because of its small systemic influence. However, it may affect daily living activities, and mental distress due to its appearance may interfere with the continuation of therapy. In this study, we surveyed the state of skin care, and found that patients had anxiety over vomiting and depilation rather than dermatopathy. Patients who developed dermatopathy performed skin care, but none performed preventive skin care. For patients to perform skin care to prevent adverse effects, we provided information on appropriate self-skin care methods based on pharmaceutical management/instruction and instruction in an outpatient chemotherapy room using documents. On conducting the second questionnaire survey after providing information, 74.3% of patients answered that information provided by pharmacists was useful. Since skin care is a form of self-care, it is necessary to continuously provide information to support patients.
Subject(s)
Antineoplastic Agents/adverse effects , Neoplasms/drug therapy , Skin Diseases/prevention & control , Adverse Drug Reaction Reporting Systems , Antineoplastic Agents/therapeutic use , Female , Humans , Male , Middle Aged , Skin Diseases/chemically induced , Surveys and QuestionnairesABSTRACT
Thirty-seven patients with advanced or recurrent colorectal cancer were treated with mFOLFOX6 or mFOLFOX6 with a Bevacizumab regimen between September 2008 and March 2009. Then, we evaluated persistent neuropathy using the National Cancer Institute Common Terminology Criteria for Adverse Events (ver. 3). As a result of the research, grade 1-3 sensory neuropathy was observed in 5.6% after 3 cycles, 44. 4% after 5 cycles, 83. 3% after 8 cycles, and 83. 4% after 10 cycles. The average dose of L-OHP (mg/m2) until persistent sensory neuropathy appeared was grade 1: 399.7+/-157. 0 (17/ 37 patients); grade 2: 418.0+/-214. 1 (5/37 patients); and grade 3: 498.0+/-152. 8 (3/37 patients). As has been shown in international clinical trials, the severity and frequency of L-OHP-induced neurotoxicity are associated with the cumulative dose and duration of L-OHP administration. Further research is necessary to develop strategies for preventing or treating this side effect.
Subject(s)
Antineoplastic Agents/adverse effects , Neurotoxicity Syndromes/etiology , Organoplatinum Compounds/adverse effects , Sensation Disorders/chemically induced , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/drug therapy , Female , Fluorouracil/adverse effects , Humans , Leucovorin/adverse effects , Male , Middle Aged , OxaliplatinABSTRACT
General treatments for breast cancer patients, such as surgery, chemotherapy, radiotherapy and lymphatic edema drainage, are performed at the Department of Breast Surgery in Kyushu Central Hospital. In those treatments, pharmacists provide the pharmaceutical treatment. Combination chemotherapy of doxorubicin and cyclophosphamide (AC therapy) is one of the standard regimens for breast cancer. In breast cancer patients who received AC therapy, we carried out investigations on side effects, and prepared pamphlets to support patients' self-management in their daily lives. In the process of preparing pamphlets, we made check sheets to monitor the severity and incidence of side effects. Based on the results of analysis and patients' opinions as well as staff remarks, we prepared pamphlets. According to the evaluation survey, pamphlets are regarded as useful. To meet the needs of patients, we intend to periodically revise pamphlets by continuing investigations on side effects, and provide up-to-date information.